The article discusses Kamada Ltd. and its position among cheap pharmaceutical stocks. It highlights the evolving pharma industry, the rise of biotechnology, and factors influencing firm valuations. Kamada's focus on plasma-based drugs and potential growth in AAT therapy make it a promising investment.